M. A. Antonsen

Medication Errors and Safety Culture in a Norwegian Hospital

M. Waaseth, E. Lehnbom, Adelina Ademi, 2019, CSHI.

The economic burden of TNFα inhibitors and other biologic treatments in Norway

W. Koldingsnes, M. Kondo, J. Norum, 2011, ClinicoEconomics and outcomes research : CEOR.

Disease First choice Second choice Ankylosing spondylitis Etanercept Adalimumab Rheumatoid arthritis First line Infliximab Etanercept second line Rituximab Psoriatic disease Efalizumab Etanercept Ulcerous colitis and fistulating Crohn ’ s disease Infliximab Crohn ’ s disease

W. Koldingsnes, M. Kondo, J. Norum, 2011 .

Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis

J. Norum, N. Helbekkmo, K. Al-Shibli, 2017, ESMO Open.